Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Intangibles (2017 - 2021)

Avalo Therapeutics' Intangibles history spans 5 years, with the latest figure at $38000.0 for Q4 2021.

  • For Q4 2021, Intangibles fell 97.6% year-over-year to $38000.0; the TTM value through Dec 2021 reached $38000.0, down 97.6%, while the annual FY2021 figure was $38000.0, 97.6% down from the prior year.
  • Intangibles reached $38000.0 in Q4 2021 per AVTX's latest filing, down from $304000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $33.1 million in Q1 2018 to a low of $38000.0 in Q4 2021.
  • Average Intangibles over 5 years is $12.6 million, with a median of $2.4 million recorded in 2019.
  • The largest YoY upside for Intangibles was 29.0% in 2021 against a maximum downside of 97.6% in 2021.
  • A 5-year view of Intangibles shows it stood at $17.7 million in 2017, then crashed by 78.68% to $3.8 million in 2018, then crashed by 35.57% to $2.4 million in 2019, then tumbled by 34.67% to $1.6 million in 2020, then plummeted by 97.6% to $38000.0 in 2021.
  • Per Business Quant, the three most recent readings for AVTX's Intangibles are $38000.0 (Q4 2021), $304000.0 (Q3 2021), and $732000.0 (Q2 2021).